←
Carlos.Parras.Team58 posts
Carlos.Parras.Team avatar

Carlos.Parras.Team

@ParrasLab
◷ Joined February 2022▧ 14 Photos and videos
Carlos.Parras.Team avatar
Carlos.Parras.Team@ParrasLab·14 Nov 2024

9/10 These findings support the repurposing of leucovorin and dyclonine for clinical trials targeting myelin disorders, offering potential therapeutic avenues for preterm brain injury and Multiple Sclerosis

Carlos.Parras.Team avatar
Carlos.Parras.Team@ParrasLab·14 Nov 2024

8/10 In an adult MS model of focal de/remyelination, they improve lesion repair by promoting OPC differentiation while preserving the OPC pool. They also shift microglia from a pro-inflammatory to a pro-regenerative profile and enhance myelin debris clearance

Post attachment
Carlos.Parras.Team avatar
Carlos.Parras.Team@ParrasLab·14 Nov 2024

7/10 In a neonatal chronic hypoxia mouse model mimicking early preterm brain injury, both compounds promote neural progenitor cell proliferation and oligodendroglial fate acquisition, with leucovorin further enhancing differentiation

Post attachment
Carlos.Parras.Team avatar
Carlos.Parras.Team@ParrasLab·14 Nov 2024

6/10 From the top 11 compounds, through in vitro neural and oligodendrocyte progenitor cell (OPC) cultures, ex vivo cerebellar explants, and in vivo mouse models of PBI and MS, we identify FDA-approved leucovorin and dyclonine as promising candidates

Post attachment
Carlos.Parras.Team avatar
Carlos.Parras.Team@ParrasLab·14 Nov 2024

5/10 OligoScore allowed us to rate and rank the pro-oligodendrogenic compounds based in their target genes being curated, selecting those impacting several processes, thus having a large pro-oligodendrogenic activities

Post attachment
Carlos.Parras.Team avatar
Carlos.Parras.Team@ParrasLab·14 Nov 2024

4/10 We then created the OligoScore resource by curating genes for which loss- & gain-of-function studies have shown their requirement in the main processes of oligodendrogenesis (categorized in specification, proliferation, …, & (re)myelination)

Post attachment
Carlos.Parras.Team avatar
Carlos.Parras.Team@ParrasLab·14 Nov 2024

3/10 We then use SPIED as a pharmacogenomic strategy to identify compounds promoting the genes of the oligodendroglial transcriptional signature obtaining 500 candidate oligodendrogenic small molecules

Post attachment
Carlos.Parras.Team avatar
Carlos.Parras.Team@ParrasLab·14 Nov 2024

2/10 We first generated transcriptional signature of oligodendroglia (oligodendrocytes and their precursor cells, OPCs), by transcriptomic comparison with other brain cells, also integrating their signature at different stages of development

Post attachment
Carlos.Parras.Team avatar
Carlos.Parras.Team@ParrasLab·14 Nov 2024

1/10 Delighted that our study using pharmacogenomics to find compounds promoting oligodendrogenesis and repair in myelin pathologies is now published in Nat Communs, after 7 years of work! rdcu.be/dZ89J (DOI: 10.1038/s41467-024-54003-9)

Italian Glia Network avatar
⟳ Carlos.Parras.Team retweeted
Italian Glia Network@italianglianet·12 Sep 2023

We invite you to become member and register for free on the website italianglianetwork.wixsite.c…, involving colleagues who may be interested in this initiative

Bassem Hassan avatar
⟳ Carlos.Parras.Team retweeted
Bassem Hassan@bassemh1·16 Jun 2023

@ShabaniDania @TheHassanLab @InstitutCerveau @ParisBrainInst paper on how the APP protein-famous for its role in Alzheimer’s disease- is actually a regulator of the tempo of human cortical development is now out in @ScienceAdvances science.org/doi/10.1126/scia…